Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2012

Jul 11, 2012

32418_dirs_2012-07-11_613597d5-eb31-484f-be4b-5340a29a7626.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-07-09

Reporting Person: Honig Barry C (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-09 Common Stock A 500000 $0.00 Acquired 4504959 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3196357 Indirect

Footnotes

F1: The restricted shares are awarded to compensate for the efforts on behalf of the Corporation.

F2: Indirect ownership includes (i) 230,000 Shares owned by GRQ Consultants, Inc. Defined Benefits Plan for the benefit of the Reporting Person; (ii) 862,786 Shares owned by GRQ Consultants, Inc. 401K of which the Reporting Person is the beneficiary; and (iii) 2,103,571 Shares owned by GRQ Consultants Inc. Roth 401K FBO Renee Honig, the Reporting Person's spouse, of which the Reporting Person has voting and investment power and disclaims beneficial ownership.